METHODS OF PROMOTING VASCULOGENESIS
Disclosed herein are methods of promoting vasculogenesis, promoting neurovasculogenesis, or treating an ischemic condition, comprising contacting a tissue with a fetal support tissue product.
1 . A method of promoting vasculogenesis of a tissue comprising endothelial cells and pericytes in an individual in need thereof, comprising reprogramming the pericytes to a first progenitor phenotype by contacting the tissue with a fetal support tissue product and reprogramming the endothelial cells to a second progenitor phenotype by contacting the tissue with the fetal support tissue product.
2 . The method of claim 1 , wherein the pericytes are selectively contacted with the fetal support tissue product.
3 . The method of claim 1 , wherein the endothelial cells are selectively contacted with the fetal support tissue product.
4 . The method of claim 1 , wherein the fetal support tissue product comprises native HC-HA/PTX3 complex, reconstituted HC-HA/PTX3 (rcHC-HA/PTX3) complex, or a combination thereof.
5 . The method of claim 4 , wherein the rcHC-HA/PTX3 complex comprises high molecular weight hyaluronic acid (HMW HA), heavy chain 1 (HC1) and heavy chain 2 (HC2) of inter-α-inhibitor (IαI) protein, and pentraxin 3 protein (PTX3).
6 . The method of claim 4 , wherein the rcHC-HA/PTX3 complex consists of HMW HA, HC1, HC2, and PTX3.
7 . The method of claim 4 , wherein the rcHC-HA/PTX3 complex consists of HMW HA, HC1, HC2, PTX3, and TSG-6.
8 . The method of claim 4 , wherein the native HC-HA/PTX3 complex is from a fetal support tissue.
9 . The method of claim 1 , wherein the tissue further comprises neural crest progenitor cells.
10 . The method of claim 9 , further comprising contacting the neural crest progenitor cells with the fetal support tissue product.
11 . The method of claim 1 , wherein the fetal support tissue product is from placenta, placental amniotic membrane, umbilical cord, umbilical cord amniotic membrane, chorion, amnion-chorion, amniotic stroma, amniotic jelly, amniotic fluid or a combination thereof.
12 . The method of any one of claims 1 - 11 , wherein the fetal support tissue product is isolated from a fetal support tissue that is frozen or previously frozen.
13 . The method of any one of claims 1 - 12 , wherein the fetal support tissue product is ground, pulverized, morselized, a graft, a sheet, micronized, a powder, a homogenate, or an extract.
14 . The method of any one of claims 1 - 13 , wherein the fetal support tissue product comprises umbilical cord amniotic membrane (UCAM).
15 . The method of claim 14 , wherein the UCAM further comprises Wharton's jelly.
16 . The method of any one of claims 1 - 15 , wherein the fetal support tissue product comprises umbilical cord that is substantially free of a vein or artery.
17 . The method of any one of claims 1 - 15 , wherein the fetal support tissue product comprises umbilical cord comprising a vein or artery.
18 . The method of any one of claims 1 - 17 , wherein the fetal support tissue product comprises a pharmaceutically acceptable excipient, carrier, or combination thereof.
19 . The method of any one of claims 1 - 18 , wherein the fetal support tissue product is formulated as a non-solid dosage form.
20 . The method of any one of claims 1 - 18 , wherein the fetal support tissue product is formulated as a solid dosage form.
21 . The method of any one of claims 1 - 18 , wherein the fetal support tissue product is formulated as a solution, suspension, paste, ointment, oil emulsion, cream, lotion, gel, a patch, sticks, film, paint, or a combination thereof.
22 . The method of any one of claims 1 - 18 , wherein the fetal support tissue product is formulated for local administration, administration by injection, topical administration, or inhalation.
23 . The method of claim 22 , wherein the fetal support tissue product is formulated for topical administration further comprises a penetration enhancer, a gelling agent, an adhesive, an emollient, or combination thereof.
24 . The method of any one of claims 1 - 23 , wherein the fetal support tissue product is formulated for controlled release.
25 . The method of any one of claims 1 - 24 , wherein the fetal support tissue product is formulated into controlled release particles, lipid complexes, liposomes, nanoparticles, microspheres, microparticles, or nanocapsules.
26 . The method of any one of claims 1 - 25 , wherein the tissue comprises ischemic tissue.
27 . The method of any one of claims 1 - 26 , wherein the tissue comprises an ulcer, wound, perforation, burn, surgery, injury, or fistula.
28 . The method of any one of claims 1 - 27 , wherein the method prevents necrosis of the tissue.
29 . The method of any one of claims 1 - 24 , further comprising selecting an individual having a tissue comprising endothelial cells and pericytes, prior to the contacting step.
30 . The method of claim 25 , wherein the selecting comprises detecting a pericyte marker in the tissue.
31 . The method of claim 26 , wherein the pericyte marker is FLK-1, CD34, CD31, α-SMA, PDGFRβ, NG2, or a combination thereof.
32 . A method of treating an ischemic tissue comprising endothelial cells and pericytes in an individual in need thereof, comprising reprogramming the pericytes to a first progenitor phenotype by contacting the tissue with a fetal support tissue product and reprogramming the endothelial cells to a second progenitor phenotype by contacting the tissue with the fetal support tissue product.
33 . The method of claim 32 , wherein the pericytes are selectively contacted with the fetal support tissue product.
34 . The method of claim 32 , wherein the endothelial cells are selectively contacted with the fetal support tissue product.
35 . The method of claim 32 , wherein the fetal support tissue product comprises native HC-HA/PTX3 complex, rcHC-HA/PTX3 complex, or a combination thereof.
36 . The method of claim 35 , wherein the rcHC-HA/PTX3 complex comprises high molecular weight hyaluronic acid (HMW HA), heavy chain 1 (HC1) and heavy chain 2 (HC2) of inter-α-inhibitor (IαI) protein, and pentraxin 3 protein (PTX3).
37 . The method of claim 35 , wherein the rcHC-HA/PTX3 complex consists of HMW HA, HC1, HC2, and PTX3.
38 . The method of claim 35 , wherein the rcHC-HA/PTX3 complex consists of HMW HA, HC1, HC2, PTX3, and TSG-6.
39 . The method of claim 35 , wherein the native HC-HA/PTX3 complex is from a fetal support tissue.
40 . The method of claim 32 , wherein the tissue further comprises neural crest progenitor cells.
41 . The method of claim 36 , further comprising contacting the neural crest progenitor cells with the fetal support tissue product.
42 . The method of claim 32 , wherein the fetal support tissue product is from placenta, placental amniotic membrane, umbilical cord, umbilical cord amniotic membrane, chorion, amnion-chorion, amniotic stroma, amniotic jelly, amniotic fluid or a combination thereof.
43 . The method of any one of claims 32 - 42 , wherein the fetal support tissue product is isolated from a fetal support tissue that is frozen or previously frozen.
44 . The method of any one of claims 32 - 43 , wherein the fetal support tissue product is ground, pulverized, morselized, a graft, a sheet, micronized, a powder, a homogenate, or an extract.
45 . The method of any one of claims 32 - 44 , wherein the fetal support tissue product comprises UCAM.
46 . The method of claim 28 , wherein the UCAM further comprises Wharton's jelly.
47 . The method of any one of claims 32 - 47 , wherein the fetal support tissue product comprises umbilical cord that is substantially free of a vein or artery.
48 . The method of any one of claims 32 - 47 , wherein the fetal support tissue product comprises umbilical cord comprising a vein or artery.
49 . The method of any one of claims 32 - 48 , wherein the fetal support tissue product comprises a pharmaceutically acceptable excipient, carrier, or combination thereof.
50 . The method of any one of claims 32 - 49 , wherein the fetal support tissue product is formulated as a non-solid dosage form.
51 . The method of any one of claims 32 - 50 , wherein the fetal support tissue product is formulated as a solid dosage form.
52 . The method of any one of claims 32 - 51 , wherein the fetal support tissue product is formulated as a solution, suspension, paste, ointment, oil emulsion, cream, lotion, gel, a patch, sticks, film, paint, or a combination thereof.
53 . The method of any one of claims 32 - 52 , wherein the fetal support tissue product is formulated for local administration, administration by injection, or topical administration.
54 . The method of any one of claims 32 - 53 , wherein the fetal support tissue product is formulated for topical administration further comprises a penetration enhancer, a gelling agent, an adhesive, an emollient, or combination thereof.
55 . The method of any one of claims 32 - 54 , wherein the fetal support tissue product is formulated for controlled release.
56 . The method of any one of claims 32 - 55 , wherein the fetal support tissue product is formulated into controlled release particles, lipid complexes, liposomes, nanoparticles, microspheres, microparticles, or nanocapsules.
57 . The method of any one of claims 32 - 56 , wherein the ischemic condition comprises cardiac ischemia, ischemic colitis, mesenteric ischemia, brain ischemia, acute limb ischemia, cyanosis, and gangrene.